InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

InterCure Ltd.NASDAQ: INCR

EPS (Diluted) · Q2 FY2025 · quarter ended Jun 2025

EPS (Diluted) turns negative

Q2 FY2025 EPS (Diluted) was -₪0.02, compared with ₪0.02 a year earlier. Trailing-twelve-month EPS (Diluted) was -₪1.61.

Context

  • EPS (Diluted) increased in 1 of the last 3 fiscal years.

What to watch

Whether next quarter's EPS (Diluted) reaches the consensus estimate of ₪0, a +100.0% change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2025
-₪0.02+0.0% QoQ
Last fiscal yearDec 2025
-₪0.63+55.6% YoY
LTMJun 2025
-₪1.61-9.5% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-200.0%+100.0%+300.0 pp
1 year+55.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

ILS · from the income statement

Latest · FY2025
(0.63) ILS
Year-over-year change
+55.6%

EPS (Diluted) vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -9.5% is the 8th highest of 9, against a peer median of +45.9%.
INCR Competitors
EPS (Diluted) for INCR and competitors
Company Period LTM YoY 3-year CAGR
FBIOFortress Biotech, Inc.LTM Mar 2026$3.18 USD+235.9%—
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$0.29 CAD+81.9%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$0.39 CAD+21.1%—
BMEABiomea Fusion, Inc.LTM Mar 2026-$0.89 USD+75.0%—
INCRInterCure Ltd.LTM Jun 2025-₪1.61 ILS-9.5%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$1.71 USD+45.1%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$2.27 USD+19.2%—
AMWLAmerican Well CorporationLTM Mar 2026-$5.42 USD+46.8%—
ASRTAssertio Holdings, Inc.LTM Mar 2026-$5.69 USD-19.1%—
Peer median (excluding INCR) —+45.9%—

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.